Astrazeneca PLC (NYSE:AZN) traded negative at $27.83. On an intraday basis, the price dropped -0.14 points or -0.5%. The composite uptick value was $0.92 million while the combined downtick value was $0.34. The net money flow was $0.58 million while the up/down ratio was not very comforting at 2.72. The shares on a weekly note has seen a change in share price of -6.39%.According to the trading data, the shares saw a block trade with $0.28 million in upticks and $0 million in downticks. The up/down ratio for the block was calculated to be 0. The net money flow for the block trade was 0.28.
Institutional Investors own 10.33% of Astrazeneca PLC shares.
Astrazeneca PLC (NYSE:AZN) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.37 points or 1.32% at $27.6 with 3,772,564 shares getting traded. Post opening the session at $27.69, the shares hit an intraday low of $27.555 and an intraday high of $27.91 and the price was in this range throughout the day. The company has a market cap of $69,828 million and the number of outstanding shares have been calculated to be 2,530,000,000 shares. The 52-week high of Astrazeneca PLC (NYSE:AZN) is $34.88 and the 52-week low is $27.555.
Many analysts have stated their opinion on the company shares. Equity analysts at the Brokerage firm Leerink Swann maintains its rating on Astrazeneca PLC (NYSE:AZN). The rating major has initiated the coverage with market perform rating on the shares. The Analysts at Leerink Swann lowers the price target from $38 per share to $34 per share. The rating by the firm was issued on May 2, 2016.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).